Going private would sound like capitulation to me.
The shorts have what is called a crowded position. The risk for them is overwhelmingly, that this time it is going to be different. I think of it as akin to a drug habit (a la a way of thinking) that they are finding hard to kick.
The company, on the other hand, is clearly doing everything possible to back the reviewers into a corner.
This of course only represents my own take. Each person is entitled to their own view and should come up with their own assessment.
Ann: Mesoblast Type A Meeting with FDA, page-61
-
- There are more pages in this discussion • 514 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |